Roche Diagnostics Expands Focus on Diabetes Care, Awaiting US Approval for Accu-Chek Smartguide CGM

July 12, 2026

Indianapolis Business Journal USA

Overview

Swiss pharmaceutical giant Roche is continuing its expansion project within its diagnostics division in Indianapolis, with an intensified focus on diabetes care. The company is particularly awaiting U.S. regulatory approval for its Accu-Chek Smartguide Continuous Glucose Monitor (CGM). While this CGM received CE Mark certification from the European Union’s health regulators in 2024 and is available in European markets, its review by the U.S. FDA is still ongoing. Continuous Glucose Monitors frequently provide real-time glucose values, enabling patients to track trends and take preventive measures against hypoglycemia and hyperglycemia.

In Depth

Key Findings

Swiss pharmaceutical major Roche is continuing its strategic expansion project at its diagnostics division in Indianapolis, with a heightened focus on the diabetes care sector. The company is particularly eager for U.S. Food and Drug Administration (FDA) approval of its Accu-Chek Smartguide Continuous Glucose Monitor (CGM). While this innovative CGM system already secured CE Mark certification from European Union health regulators in 2024 and is available in European markets, its entry into the U.S. market is significantly contingent on the FDA’s review outcome. Continuous Glucose Monitors provide frequent, real-time blood glucose data, enabling diabetic patients to identify trends in glucose fluctuations and take proactive measures against dangerous states like hypoglycemia and hyperglycemia.

Technical/Clinical Details

The Accu-Chek Smartguide CGM continuously measures interstitial fluid glucose levels via a small sensor worn on the skin, transmitting this data wirelessly to compatible receivers or smartphone applications. This system enhances the precision and convenience of glucose management by providing users with current glucose readings, historical trends, and future glucose predictions. Critically, its ability to issue alerts when glucose levels exceed predefined thresholds for hypoglycemia or hyperglycemia is vital for ensuring patient safety. The CE Mark certification in Europe signifies that the device conforms to rigorous European health, safety, and environmental protection standards, underscoring its clinical efficacy and reliability. The FDA’s review aims to evaluate additional data regarding the device’s safety and effectiveness in the specific U.S. patient population.

Background and Industry Context

Diabetes is a globally escalating chronic disease, and effective glucose management is essential for preventing complications and maintaining quality of life. Continuous Glucose Monitoring (CGM) technology has dramatically transformed the paradigm of diabetes management by overcoming the limitations of traditional finger-prick self-monitoring of blood glucose (SMBG) and HbA1c tests, offering more comprehensive and real-time glucose data. Roche Diagnostics has been a key player in the diabetes care sector for many years, providing blood glucose meters through its Accu-Chek brand. This intensified focus on CGM and expansion into the U.S. market signifies Roche’s strategic shift towards digital health and integrated diabetes management solutions, aiming to strengthen its competitive position in the rapidly growing CGM market.

Strategic Significance & Outlook

U.S. FDA approval for the Accu-Chek Smartguide CGM will be a significant milestone for Roche Diagnostics. Once approved, Roche will substantially enhance its presence in the U.S. CGM sector and leverage its existing Accu-Chek brand customer base to offer innovative monitoring solutions to a wide range of diabetic patients. This will further accelerate CGM adoption in the U.S. market, allowing more diabetic patients to benefit from higher quality, personalized glucose management. In the future, advancements in ‘closed-loop systems’ (artificial pancreas) integrating CGM data with insulin pumps, and the evolution of AI-powered glucose prediction algorithms, are expected to further automate diabetes management and reduce patient burden. Roche’s strategy is poised to play a crucial role in shaping the future of diabetes care.

Source: https://www.ibj.com/articles/roche-diagnostics-expansion-to-focus-on-diabetes-care

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.